EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

As-Needed Albuterol–Budesonide in Mild Asthma

Craig LaForce, Frank Albers iD, Anna Danilewicz, Allison Jeynes-Ellis, Monica Kraft, Reynold A Panettieri, Robert Rees, Samuel Bardsley, Lynn Dunsire, Tim Harrison, Olami Sobande, Raulin Surujbally und 10 weitere

New England Journal of Medicine · 10.07.2025 · 393 (2) · 113-124

DOI: 10.1056/nejmoa2504544 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 10.07.2025. Verfasst von Craig LaForce und 21 weiteren Autor:innen. Beteiligte Einrichtung: North Carolina Clinical Research, Raleigh. Hauptthemen laut MEDLINE: Adrenergic beta-2 Receptor Agonists, Albuterol, Asthma, Bronchodilator Agents. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: AstraZeneca, Bond Avillion 2 Development LP.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic beta-2 Receptor AgonistsAlbuterolAsthmaBronchodilator AgentsBudesonideAdolescentAdultAgedChildFemaleHumansMaleMiddle AgedYoung AdultAdministration, InhalationDisease ProgressionDouble-Blind MethodDrug CombinationsGlucocorticoidsSeverity of Illness IndexTreatment Outcome

Substanzen

Adrenergic beta-2 Receptor AgonistsAlbuterolBronchodilator AgentsBudesonideDrug CombinationsGlucocorticoids

Autor:innen und Institutionen

  • North Carolina Clinical Research, Raleigh.
  • Avillion US, Northbrook, IL.
  • Avillion Life Sciences, London.
  • Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, New York.
  • Rutgers Institute for Translational Medicine and Science, Rutgers, State University of New Jersey, New Brunswick.
  • BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, United Kingdom.

ORCID-Profile: Frank Albers, Richard Beasley

Förderung

  • AstraZeneca
  • Bond Avillion 2 Development LP

Zitieren

APA

LaForce, C., Albers, F., Danilewicz, A., Jeynes-Ellis, A., Kraft, M., Panettieri, R. A., Rees, R., Bardsley, S., Dunsire, L., Harrison, T., Sobande, O., Surujbally, R., Trudo, F., Cappelletti, C., Papi, A., Beasley, R., Chipps, B. E., Israel, E., Pandya, H., …, & BATURA Investigators (2025). As-Needed Albuterol–Budesonide in Mild Asthma. New England Journal of Medicine, 393(2), 113-124. https://doi.org/10.1056/nejmoa2504544

Vancouver

LaForce C, Albers F, Danilewicz A, Jeynes-Ellis A, Kraft M, Panettieri RA, et al. As-Needed Albuterol–Budesonide in Mild Asthma. New England Journal of Medicine. 2025;393(2):113-124. doi:10.1056/nejmoa2504544

BibTeX
@article{LaForce2025,
  author = {LaForce, Craig and Albers, Frank and Danilewicz, Anna and Jeynes-Ellis, Allison and Kraft, Monica and Panettieri, Reynold A and Rees, Robert and Bardsley, Samuel and Dunsire, Lynn and Harrison, Tim and Sobande, Olami and Surujbally, Raulin and Trudo, Frank and Cappelletti, Christy and Papi, Alberto and Beasley, Richard and Chipps, Bradley E and Israel, Elliot and Pandya, Hitesh and Clancy, Martin and Bacharier, Leonard B and BATURA Investigators, BATURA Investigators},
  title = {As-Needed Albuterol–Budesonide in Mild Asthma},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {2},
  pages = {113--124},
  doi = {10.1056/nejmoa2504544}
}
Kostenlos starten →